Skip to main content

Table 4 Overview of safety outcomes (Safety population)

From: A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Adverse events (AEs), n (%) BTH1677/
Bevacizumab/
Carboplatin/Paclitaxel
(N = 59)
Bevacizumab/
Carboplatin/
Paclitaxel
(N = 30)
Any AE 58 (98.3) 30 (100.0)
NCI/CTCAE Grade 3 or 4 AEs 55 (93.2) 20 (66.7)
Serious AEs 24 (40.7) 13 (43.3)
BTH1677-related AEs   
Probably related 13 (22.0) NA
Possibly related 17 (28.8) NA
AEs leading to discontinuation 21 (35.6) 12 (40.0)
  1. Abbreviations: AE adverse events, N overall sample size, n number of patients, NA not applicable, NCI/CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events